The transaction is expected to close during the first half of 2012 and is not subject to a funding condition. Cordani, President and CEO. Our two companies talk about a common strategic vision and philosophy that people create customer value by partnering with health care professionals, and use details and incentives to provide high-quality, differentiated programs. We are thrilled to announce this transaction with Cigna, stated Herb Fritch. Carrying out a review undertaken by our Panel of Directors of the business’s strategic options, we concluded that the mixture is in the very best interests of our shareholders. The combination may also expand our ability to serve our doctor partners and customers.We are very happy to have received this money award, and will utilize the funds to advance our objectives for item commercialization, said Mesoblast Chief Executive Professor Silviu Itescu. Related StoriesUS and German researchers team up to advance quality control of human stem cellsFranziska Michor named recipient of NYSCF – Robertson Stem Cell PrizePublic plan needed to decrease stem cell tourism, state expertsThe QTDP plan was enacted as part of the Patient Security and Affordable Care Work of 2010 to provide tax credits to eligible businesses in order to encourage investments in new therapies for prevention or treatment of acute and chronic diseases. To be eligible for the program, projects had showing reasonable potential to result in new therapies to treat regions of unmet medical require, prevent, detect, or treat persistent or severe disease and conditions, or reduce long-term health care costs in the United States.